Synlogic, Caldera Therapeutics Announce All
Synlogic and Caldera Therapeutics agreed to merge in an all-stock deal creating a Nasdaq-listed biotech under the Caldera name, targeting ticker CALD. Caldera secured $278 million in private placement funding plus existing cash to fund operations into 2029. Proceeds support Phase 2 trials of CLD-423 in ulcerative colitis and Crohn’s disease; Phase 1 data show good tolerability and >40-day half-life.
How this was made
The 30-second read
Why it matters
The announcement combines (1) a merger with defined ownership percentages, (2) a $278M private placement to fund operations into 2029, and (3) Phase 2 advancement plans for CLD-423 based on Phase 1 tolerability and PK/PD signals.
Market read
Traders can frame near-term catalysts around merger approvals, SEC registration effectiveness, and the financing’s role in de-risking Phase 2 timelines.
What to watch
Key execution risks remain: Phase 1 single-dose results may not translate to efficacy, and deal closing depends on SEC registration statement effectiveness and shareholder approvals.
Background
Synlogic and Caldera announced an all-stock merger intended to create a Nasdaq-listed IBD-focused biotech under the Caldera name.
Ticker impact
Synlogic agreed to an all-stock merger with Caldera, with its shareholders expected to own about 2.3% of the combined company.
Likely volatility around deal mechanics, ownership dilution, and the path to Nasdaq listing under the new ticker.
The article discloses merger structure, ownership splits, and expected closing timeline, which typically drives trading ahead of shareholder and SEC registration milestones.
Market effects
Signals continued investor appetite for IBD immunology assets and bispecific TL1A/IL-23p19 pathway strategies.
Limited direct regional impact; primarily US biotech capital markets and Nasdaq listing mechanics.
Global rights to CLD-423 and an Australia Phase 1 program underscore cross-border clinical development and commercialization planning.
Counterpoint
The ownership split implies meaningful dilution for existing Synlogic holders, and the combined company’s success still hinges on Phase 2 outcomes.
Key entities
- companySynlogic, Inc.
Agreed to an all-stock merger with Caldera; its shareholders expected to own about 2.3% of the combined company.
- companyCaldera Therapeutics, Inc.
Will operate the merged entity under the Caldera name, seek Nasdaq listing under ticker CALD, and raise $278M via private placement.
- assetCLD-423
Experimental bispecific antibody targeting TL1A and IL-23p19, intended for Phase 2 in ulcerative colitis and Crohn’s disease.
- partnerQyuns Therapeutics Co., Ltd.
Licensing agreement provides Caldera exclusive global rights to develop and commercialize CLD-423.
